Lung cancer claims the lives of more people than any other cancer worldwide. In the US, lung cancer is the third most commonly diagnosed cancer. In 2018, there were approximately 234,030 new cases diagnosed and over 154,000 lung cancer related deaths. Lung cancers are histologically (microscopic tissue structure) defined as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), accounting for 15% and 85% of cases, respectively. Adenocarcinoma is the most common subtype of NSCLC. Because early lung cancer is largely asymptomatic, more than half of the cases have metastasized at the time of diagnosis.
The treatment landscape for metastatic lung cancer has changed significantly with the development of targeted oral therapies and immune checkpoint inhibitor (ICPI) therapy. Unlike chemotherapy, targeted oral therapy blocks the growth and spread of cancer cells; not all cells. ICPIs help the immune system distinguish between cancer and normal cells, allowing the immune system to attack the cancer cells. Like most new oncology treatments, ICPIs were initially approved for use later in the sequence of treatment options – but are now standard of care, first-line treatments for some patients. This article will not review ICPIs, but instead focus on the targeted oral therapies available for the treatment of metastatic NSCLC. More patients are receiving longterm, targeted oral therapies due to extended progression-free survival with these medications compared to chemotherapy...
- Pharmacy Technicians
This CE activity was developed by The Rx Consultant, a publication of Continuing Education Network, Inc.
CE activities for Pharmacists and Pharmacy Technicians:
This continuing education (CE) activity meets the requirements of all state boards of pharmacy for approved continuing education hours. CE credit is automatically reported to CPE Monitor.
CE activities for Nurse Practitioners and Clinical Nurse Specialists:
This continuing education activity meets the requirements of:
The American Nurses Credentialing Center (ANCC) for formally approved continuing education (CE) hours, and CE hours of pharmacotherapeutics.
The American Academy of Nurse Practitioners Certification Program (AANPCP) for acceptable, accredited CE.
This is a pharmacotherapeutics/pharmacology CE activity.
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Requirements for CE Credit
- State the genetic mutations or gene rearrangements that a stage IV non-small cell lung cancer patient may have in which a targeted oral therapy is recommended. Recognize the medications that target each specific mutation.
- List the brand and generic names of the oral targeted therapies discussed in this issue; identify 3 possible side effects of each.
- Recognize the usual starting dose range for each targeted oral therapy discussed in this issue. List the recommended administration instructions for each.
Shannon M. Hough, PharmD, BCOP
Brief Bio : Shannon M. Hough, PharmD, BCOP is the Pharmacy Manager of Oncology Clinical Services at Michigan Medicine and an adjunct Clinical Assistant Professor at the University of Michigan College of Pharmacy in Ann Arbor, MI. She is also a thoracic oncology clinical pharmacist specialist at the University of Michigan Rogel Cancer Center in Ann Arbor.